Nomura Asset Management Co. Ltd. Buys 23,238 Shares of Novo Nordisk A/S (NYSE:NVO)

Nomura Asset Management Co. Ltd. boosted its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 113.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 43,776 shares of the company's stock after acquiring an additional 23,238 shares during the period. Nomura Asset Management Co. Ltd.'s holdings in Novo Nordisk A/S were worth $3,766,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently modified their holdings of the business. LM Advisors LLC acquired a new position in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $208,000. Loomis Sayles & Co. L P lifted its position in Novo Nordisk A/S by 34.2% in the 4th quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company's stock valued at $995,397,000 after acquiring an additional 2,947,771 shares in the last quarter. Sava Infond d.o.o. acquired a new position in Novo Nordisk A/S in the 4th quarter worth $1,591,000. Graney & King LLC acquired a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at about $52,000. Finally, Murphy & Mullick Capital Management Corp bought a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $530,000. Institutional investors and hedge funds own 11.54% of the company's stock.

Analysts Set New Price Targets

NVO has been the topic of a number of recent research reports. Kepler Capital Markets raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. StockNews.com lowered shares of Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research report on Friday, March 21st. UBS Group raised shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research report on Wednesday, January 8th. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. Finally, BMO Capital Markets dropped their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a report on Monday, December 23rd. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Novo Nordisk A/S has a consensus rating of "Moderate Buy" and a consensus target price of $145.25.

Remove Ads

Novo Nordisk A/S Stock Performance

NYSE NVO traded up $0.17 during trading on Wednesday, reaching $68.20. 7,301,268 shares of the company's stock were exchanged, compared to its average volume of 5,593,302. Novo Nordisk A/S has a fifty-two week low of $66.33 and a fifty-two week high of $148.15. The business has a 50 day moving average price of $81.89 and a 200-day moving average price of $97.68. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The stock has a market capitalization of $306.05 billion, a P/E ratio of 20.73, a PEG ratio of 0.90 and a beta of 0.42.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Sell-side analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be paid a $0.7874 dividend. The ex-dividend date of this dividend is Monday, March 31st. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. This represents a yield of 1.2%. Novo Nordisk A/S's payout ratio is 47.72%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.